BioSpace News Archive

Mallinckrodt plc, a global biopharmaceutical company, announced that it will report second quarter 2019 earnings results for the period ending June 28, 2019 on Tuesday, Aug. 6, 2019.

Merck’s supply chain and eCommerce strength will allow broader availability and accessibility of the Fire Monkey / Fire Flower product to customers

The emergence of targeted therapies for the treatment of bone cancer is expected to drive market growth.

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, provided a mid-calendar year update on its corporate and clinical development programs.

Patients Receiving Givosiran in Pivotal Phase 3 ENVISION Study had a 74 Percent Mean Reduction in Annualized Rate of Composite Porphyria Attacks Compared to Placebo

Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies

This is the second acquisition of its kind by Carenet in seven months.

ZULRESSO is the 11th FDA-approved drug to use Ligand’s patented Captisol technology.

This new addition brings AWG’s membership to 14 antimicrobial drug companies

Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer’s and Parkinson’s that are focused on regeneration, today announced that Leen Kawas, President and CEO of Athira, has been selected as a member of the French-American Foundation’s 2019 class of Young Leaders.